Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3187-3194

  Gaofu, Qi ^a   Dan, Mao ^a   Jie, Wu ^a   Liao, Zhongping ^a   Li, Zong ^a   Roque, Rouel S ^b   Jingjing, Liu ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibody; Atherosclerosis; Carrier molecule; Cholesteryl ester transfer protein; Heat shock protein; Vaccine

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HEAT SHOCK PROTEIN 65; RECOMBINANT VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION EXCHANGE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; MOLECULAR DYNAMICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBERCULOSIS; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; BACTERIAL PROTEINS; BCG VACCINE; BLOTTING, WESTERN; CARRIER PROTEINS; CHAPERONINS; CHOLESTEROL ESTER TRANSFER PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; GLYCOPROTEINS; IMMUNITY, MUCOSAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3843105896     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.01.060     Document Type: Article

References (24)

1. Barrios C., Lussow A.R., Van Embden J., Van der Zee R., Rappuoli R., Costantino P., et al. Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming. Eur J Immunol. 22:1992;1365-1372
2. Perraut R., Lussow A.R., Gavoille S., Garraud O., Matile H., Tougne C., et al. Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants. Clin. Exp. Immunol. 93:1993;382-386
3. Barrios C., Tougne C., Polla B.S., Lambert P.H., Del Giudice G. Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kDa. Clin Exp Immunol. 98:1994;224-228
4. Tall A.R. Plasma cholesteryl ester transfer protein. J Lipid Res. 34:1993;1255-1274
5. Barter P., Rye K.A. Cholesteryl ester transfer protein: its role in plasma lipid transport. Clin Exp Pharmacol Physiol. 21:1994;663-672
6. Tall A.R. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J Int Med. 237:1995;5-12
7. Asztalos B.F., Schaefer E.J. HDL in atherosclerosis: actor or bystander? Atheroscler Suppl. 4:2003;21-29
8. Whitlock M.E., Swenson T.L., Ramakrishnan R., Leonard M.T., Marcel Y.L., Milne R.W., et al. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest. 84:1989;129-137
9. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 20:2000;2106-2112
10. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H., et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 273:1998;5033-5036
11. Swenson T.L., Hesler C.B., Brown M.L., Quinet E., Trotta P.P., Haslanger M.F., et al. Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. J Biol Chem. 264:1989;14318-14326
12. Jingjing L., Xue Y., Agarwal N., Roque R.S. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 40:1999;752-759
13. Mitra D.K., Mehra N.K., Maiti T.K., Banerjee A., Taneja V., Rajalingam R., et al. CD4 + T-cell responses to recombinant hsp65 and hsp18 of M. leprae and their trypsin-digested fragments in leprosy: diversity in HLA-DR restriction. Int J Lepr Other Mycobact Dis. 63:1995;518-528
14. Chu N.R., Wu H.B., Wu T.C., Boux L.J., Mizzen L.A., Siegel M.I. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7A. Cell Stress Chaperones. 5:2000;401-405
15. Portaro F.C., Hayashi M.A., De Arauz L.J., Palma M.S., Assakura M.T., Silva C.L., et al. The Mycobacterium leprae hsp65 displays proteolytic activity. Mutagenesis studies indicate that the M. leprae hsp65 proteolytic activity is catalytically related to the HslVU protease. Biochemistry. 41:2002;7400-7406
16. Thole J.E., Keulen W.J., De Bruyn J., Kolk A.H., Groothuis D.G., Berwald L.G., et al. Characterization, sequence determination, and immunogenicity of a 64-kilodalton protein of Mycobacterium bovis BCG expressed in Escherichia coli K-12. Infect Immunol. 55:1987;1466-1475
17. Lea I.A., Kurth B., O'Rand M.G. Immune response to immunization with sperm antigens in the macaque oviduct. Biol Reprod. 58:1998;794-800
18. Afzalpurkar A., Shibahara H., Hasegawa A., Koyama K., Gupta S.K. Immunoreactivity and in-vitro effect on human sperm-egg binding of antibodies against peptides corresponding to bonnet monkey zona pellucida-3 glycoprotein. Hum Reprod. 12:1997;2664-2670
19. Thau R. Anti-LHRH and anti-pituitary gonadotropin vaccines: their development and clinical applications. Scand J Immunol Suppl. 11:1992;127-130
20. Mettens P., Monteyne P. Life-style vaccines. Br Med Bull. 62:2002;175-186
21. Rafii S. Vaccination against tumor neovascularization: Promise and reality. Cancer Cell. 2:2002;429-431
22. Wei Y.Q., Huang M.J., Yang L., Zhao X., Tian L., Lu Y., et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA. 98:2001;11545-11550
23. Niethammer A.G., Xiang R., Becker J.C., Wodrich H., Pertl U., Karsten G., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 8:2002;1369-1375
24. Liu J.Y., Wei Y.Q., Yang L., Zhao X., Tian L., Hou J.M., et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2A. Blood. 102:2003;1815-1823